Want to see TSE:PREV full AI Analyst Report?
PREV Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.06
Previous CloseN/A
Volume42.00K
Average Volume (3M)133.90K
Market Cap
C$12.76M
Enterprise ValueC$13.85
Total Cash (Recent Filing)C$35.66K
Total Debt (Recent Filing)C$4.84M
Price to Earnings (P/E)―
Beta-0.43
Next Earnings
Nov 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding638,186,950
10 Day Avg. Volume285,967
30 Day Avg. Volume133,899
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Asset BaseAsset growth compared with 2024 provides a limited constructive signal about the company’s resource base. Although this improvement does not offset negative equity or leverage, a larger asset base may support ongoing research programs and future commercialization efforts over the next several quarters.
Diversified R&D FocusResearch spanning cannabinoids, pain management, nutraceuticals and delivery technologies gives the company multiple avenues for developing products and intellectual property. This breadth could support future partnering or commercialization opportunities, although the programs remain development-focused rather than established revenue sources.
Licensing PotentialThe stated model includes monetizing intellectual property through licensing or strategic partnerships, which could provide an asset-light route to future revenue if candidates or delivery technologies attract commercial partners. That mechanism offers potential scalability beyond direct product sales.
Bears Say
No Demonstrated RevenueZero reported revenue across the available periods indicates that the company has not yet demonstrated commercial traction from its pharmaceutical, nutraceutical or delivery-technology programs. Without recurring sales, future funding and growth depend heavily on successful development, partnering or product commercialization.
Negative Equity And High LeveragePersistent negative equity and debt substantially above the asset base signal a weak capital structure and limited financial flexibility. This may constrain investment in research and commercialization while increasing dependence on external financing and making the company more vulnerable to solvency pressure.
Ongoing Cash BurnContinued operating and free-cash-flow deficits show that the business is consuming cash rather than funding itself. The reported deterioration in TTM free cash flow suggests funding needs may be rising, potentially requiring additional financing or dilution before commercialization generates sustainable cash inflows.
PreveCeutical Medical News
PREV FAQ
What was PreveCeutical Medical Inc’s price range in the past 12 months?
PreveCeutical Medical Inc lowest stock price was C$0.01 and its highest was C$0.06 in the past 12 months.
What is PreveCeutical Medical Inc’s market cap?
PreveCeutical Medical Inc’s market cap is C$12.76M.
When is PreveCeutical Medical Inc’s upcoming earnings report date?
PreveCeutical Medical Inc’s upcoming earnings report date is Nov 19, 2026 which is in 69 days.
How were PreveCeutical Medical Inc’s earnings last quarter?
PreveCeutical Medical Inc released its earnings results on Aug 28, 2026. The company reported -C$0.002 earnings per share for the quarter.
Is PreveCeutical Medical Inc overvalued?
According to Wall Street analysts PreveCeutical Medical Inc’s price is currently Overvalued.
Does PreveCeutical Medical Inc pay dividends?
PreveCeutical Medical Inc does not currently pay dividends.
What is PreveCeutical Medical Inc’s EPS estimate?
PreveCeutical Medical Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PreveCeutical Medical Inc have?
PreveCeutical Medical Inc has 638,186,950 shares outstanding.
What happened to PreveCeutical Medical Inc’s price movement after its last earnings report?
PreveCeutical Medical Inc reported an EPS of -C$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PreveCeutical Medical Inc?
Currently, no hedge funds are holding shares in TSE:PREV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PreveCeutical Medical Inc
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid Sol-Gel Delivery system, a cannabinoid-based technology designed for nose-to-brain delivery, aiming to alleviate symptoms associated with pain, inflammation, epileptic seizures, and diverse neurological conditions. Also in development is the BSV Peptide Program, which focuses on hindering cancer's advancement, alongside a non-addictive analgesic for effective pain relief. The company is also progressing with a Dual Gene Therapy project to address type 2 diabetes and obesity. Complementing these initiatives, PreveCeutical is involved in the creation of various products derived from medicinal cannabis. The company is headquartered in Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
BetterLife Pharma
―
―
MYND Life Sciences
―
PharmAla Biotech Holdings, Inc.
―